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A llogeneic stem cell transplantation (allo-SCT) is recognized as a curative therapy for advanced 
hematologic malignancies,  but the relapse of the origi-
nal malignancy after allo-SCT remains one of the most 
common causes of treatment failure and mortality.  
Second allo-SCT or donor lymphocyte infusion shows 
potential as a definitive cure in these patients [1 , 2],  but 
only a limited proportion of relapsed patients are able to 
receive these intensive treatments.
One of the difficulties in conducting a second SCT is 
donor availability.  Only about one-third of the patients 
have a human leukocyte antigen (HLA)-matched sibling 
donor,  and identifying and mobilizing an unrelated 
adult donor could take longer than three months.  
Relapsed patients are often in poor condition physically,  
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Second allogeneic stem cell transplantation (allo-SCT) is a potentially curative therapy for patients who relapse 
after first allo-SCT.  Human leukocyte antigen (HLA)-haploidentical related donors provide the broad opportu-
nity to conduct second SCT at the appropriate time,  but the efficacy of second SCT from haploidentical donors 
after relapse has not been established.  We retrospectively analyzed the records of 33 patients who underwent 
second SCT.  Twenty patients underwent haplo-SCT with low-dose antithymocyte globulin (ATG),  and the 
other 13 patients underwent conventional- SCTs,  including HLA-matched related peripheral blood,  unrelated 
bone marrow or cord blood.  Three years after the second SCT,  the overall survival (OS) and progression-free 
survival (PFS) of all patients were 32.5% and 23.9%.  Multivariate analyses indicated that non-complete 
response at second SCT,  less than 1-year interval to relapse after first- SCT,  and total score ≥ 3 on the hemato-
poietic cell transplantation-specific comorbidity index were significantly associated with a lower PFS rate.  The 
haplo- and conventional- SCT groups showed equivalent results regarding OS,  PFS,  cumulative incidences of 
relapse,  non-relapse mortality and graft-versus-host disease.  The neutropenic period after transplantation was 
significantly shorter in haplo- SCT than conventional- SCT (10.5 days vs. 16 days,  p= 0.001).  Our analysis 
revealed that haplo-SCT could be an alternative therapeutic option for relapsed patients after first SCT.
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and there is a greater likelihood for more aggressive 
disease after relapse; therefore,  rapid access to the 
appropriate donor graft is critical from the clinical 
viewpoint.  HLA-haploidentical family donors should be 
considered a potential option for the graft of the second 
SCT,  as the possibility of identifying an HLA-
haploidentical donor in a family is over 90% [3].  The 
last decade has seen substantial improvements in hap-
loidentical transplantations (haplo-SCTs),  which has 
enabled the use of haploidentical donors more readily 
[4].
Several studies have reported similar good clinical 
outcomes in patients with various hematological malig-
nancies who received transplants from matched unre-
lated donors compared to those who received trans-
plants from haploidentical related donors.  [5-8] 
However,  to the best of our knowledge,  no study has 
directly analyzed the outcomes in relapsed patients who 
underwent a second haplo-SCT compared to those who 
received second SCTs from other sources (i.e.,  HLA-
matched siblings,  HLA-matched unrelated donors,  
umbilical cord blood.  or partially HLA-mismatched 
unrelated donors) after their first allo-SCT at a single- 
institute during the same time period.  We thus con-
ducted the present retrospective analysis of patients 
who underwent a second allo-SCT for their relapse of 
hematologic malignancies after a first allo-SCT,  in order 
to assess the safety and efficacy of haplo-SCT in these 
patients.
Patients and Methods
Patients. This study included all consecutive 
adult patients at Okayama University Hospital who 
underwent a second allo-SCT during the period from 
January 2007 to December 2016 for the treatment of a 
relapse of their underlying disease after the first allo-
SCT.  Twenty patients received an HLA-haploidentical 
peripheral blood (PB) transplants (the haplo-SCT 
group).  Thirteen patients received an HLA-matched or 
partially mismatched transplants,  three underwent cord 
blood transplantation (CBT),  3 underwent related 
peripheral blood SCT (rPBSCT),  and 7 underwent 
unrelated bone marrow transplantation (BMT).  These 
patients who underwent a conventional transplant were 
assigned to the control group.
The outcomes of interest were the overall survival 
(OS),  progression-free survival (PFS),  cumulative inci-
dence of relapse (CIR),  non-relapse mortality (NRM),  
acute graft-versus-host disease (aGVHD),  chronic 
GVHD (cGVHD),  engraftment,  and the time to plate-
let and neutrophil recovery.  We defined the OS,  CIR 
and NRM as the number of days from the second SCT 
until death from any cause,  relapse,  and death without 
relapse,  respectively.  The conditioning intensity was 
classified as myeloablative conditioning (MAC) versus 
reduced intensity conditioning (RIC).  [9] The hemato-
poietic cell transplantation-specific comorbidity index 
(HCT-CI) was collected for all patients.  [10] The day of 
platelet recovery was defined as the first day on which 
the platelet count reached or exceeded 20 × 109/L with-
out transfusion.  The day of neutrophil recovery was 
defined as the first of 3 consecutive days on which the 
absolute neutrophil count exceeded 5 × 109/L.  The 
International Bone Marrow Transplant Registry criteria 
were used for the aGVHD staging,  [11] and the Seattle 
criteria were used to determine cGVHD severity.  [12] 
Information on baseline demographics,  clinical charac-
teristics,  and transplantation and its outcomes were 
collected from their medical records.
The conditioning regimens for the second SCTs.
The conditioning regimens for the second SCTs are 
detailed in Table 1.  The conditioning regimens included 
fludarabine (Flu),  busulfan (BU),  melpharan (Mel) and 
cytarabine (CY),  and the regimes for the haplo-SCT 
cohort were classified into the following 3 groups: Flu/
BU-based (n = 14),  Flu/Mel-based (n = 5),  and Flu/
CY-based (n = 1).  In addition,  low-dose rabbit antithy-
mocyte globulin (ATG) was added to all regimens in the 
haplo-SCT group.  For the patients with decreased renal 
function,  the doses of Flu,  Mel,  and CY were adjusted 
according to the residual renal function levels.  All hos-
pitalized patients stayed in a dedicated inpatient unit in 
laminar airflow rooms with standard infection control 
procedures.  For the haplo group,  the GVHD prophy-
laxis consisted of tacrolimus and methylprednisolone.  
For the control group,  combinations of cyclosporine or 
tacrolimus and short-term methotrexate were used.
Statistical analyses. We compared the primary 
study variables between the haploidentical group and 
the control group using Fisher’s exact test (categorical 
variables) and the Mann–Whitney U-test (continuous 
variables).  The Kaplan-Meier method was used to esti-
mate OS and PFS.  We used the log-rank test to assess 
group differences in OS and PFS.  Cox proportional 
hazard regression models were fit for our evaluation of 
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the prognostic effects of demographic and clinical mea-
sures of interest on the OS and PFS.  The cumulative 
incidence (CI) curves of relapse,  transplant-related 
mortality (TRM),  acute GVHD,  and neutrophil and 
platelet recovery were estimated using the CI function.  
The competing risks for relapse and TRM included 
death and relapse,  respectively.  The competing risks for 
acute GVHD included death and relapse.  [13] Death 
without count recovery was considered a competing 
risk for count recovery.  The CI curves were compared 
using Gray’s test.  All tests of significance were two-
sided,  and p-values < 0.05 were considered significant.  
Statistical analyses were performed with EZR (Saitama 
Medical Centre,  Jichi Medical University,  Saitama,  
Japan),  which is a graphical user interface for R (The R 
Foundation for Statistical Computing,  Vienna,  Austria,  
2.13.0) [14].
Results
Patient characteristics. The characteristics of the 
33 consecutive patients who underwent a second SCT 
are summarized in Table 2.  The median age of the 
patients in the haplo group was 49.5 years (range 19-64 
years),  and that of the control group 54 years (range 
19-69 years) (p = 0.58).  There were no significant differ-
ences in sex (p = 0.148),  HCT-CI score (p = 0.431),  or 
hematopoietic progenitor cells (HPCs) for the first SCT 
(p= 0.31).  Preparative regimens for the first SCT did not 
differ significantly; 12 of 20 (60%) patients in the haplo 
group had undergone a TBI-based preparative regimen 
compared to 5 (38.5%) patients in the control group 
(p = 0.097).  The median time from the first SCT to the 
relapse diagnosis in the haplo group (232.5 days;  
range,  57-1,004 days) was significantly shorter than that 
in the control group (667 days; range,  84-2,235 days) 
(p = 0.009).  The median time between the first and sec-
ond SCTs in the haplo group (388 days,  range 85-1,144 
days) was significantly shorter than that in the control 
group (833 days,  range 252-3,123 days) (p= 0.027).  The 
median time between the relapse and second SCT 
(p = 0.428) and the period of the second SCT (p = 0.27) 
did not differ significantly between the haplo and con-
trol groups.  The diagnoses for the second SCT included 
acute myeloid leukemia (AML),  myelodysplastic syn-
drome (MDS),  acute lymphoblastic leukemia (ALL),  
malignant lymphoma (ML) and adult T-cell leukemia 
(ATL),  with no significant difference between the haplo 
and control groups (p = 0.839).  The indication for sec-
ond SCT was the same as that for the first SCT in the 
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Table 1　 Second transplant preparative regimens
Regimen
Type (no. of patients)
BU
mg/kg
TBI
cGy
Flu
mg/m2
CY
mg/kg
Mel
mg/m2
VP-16
mg/kg
AraC
g/m2
ATG
mg/kg
Haplo (20)
　Flu-BU-ATG (3) 6.4 180 8
　Flu-BU-ATG (4) 6.4 180 2.5
　Flu-BU-ATG (1) 12.8 180 2.5
　AraC-Flu-BU-ATG (2) 6.4 180 8 2.5
　AraC-Flu-BU-ATG (4) 12.8 180 4.4 2.5
　Flu-Mel-TBI-ATG (3) 400 180 140 2.5
　AraC-Flu-Mel-TBI-ATG (2) 400 180 140 8 2.5
　AraC-Flu-CY-TBI-ATG (1) 400 120 120 8 2.5
Control (13)
　Flu-CY (1) 180 50
　Flu-BU (4) 6.4 180
　Flu-Mel (2) 125 140
　BU-CY (1) 16 (p.o.) 120
　BU-CY-VP-16 (1) 12.8 120 30
　Flu-TBI (1) 200 125
　Flu-BU-TBI (1) 6.4 200 180
　Flu-BU-TBI (1) 6.4 400 180
　Flu-Mel-TBI (1) 400 125 140
Flu,  ﬂudarabine; BU,  busulfan; Mel,  melpharan; CY,  cytarabine; TBI,  total body irradiation; ATG,  antithymocyte globulin; AraC,  cytar-
abine; haplo,  haploidentical; VP-16,  etopiside.
majority of cases.  The disease status at the first and 
second SCTs (p = 1.000 and 0.728,  respectively),  donor 
leukocyte infusion (DLI) before the second SCT 
(p = 0.202),  and the conditioning intensity for the sec-
ond SCT (p = 1.000) did not differ significantly between 
the haplo and control groups.
Overall survival and progression-free survival.
The median follow-up time was 1,276 days (range 505-
3,747 days) among the survivors.  At the 3-year fol-
low-up,  the OS and PFS rates of all patients who 
underwent a second SCT were 32.5% (95% CI 17.3-
48.7%) and 23.9% (95% CI 10.2-40.6%),  respectively 
(Fig. 1A and B).  There were no significant differences in 
OS at 3 years between the haplo and control groups;  
25.0% (95% CI 9.1-44.9%) and 44.9% (95% CI 17.7-
69.0%),  respectively(p = 0.366) (Fig. 2A,  Table 3).  The 
PFS at 3 years was 25.0% (95% CI,  9.1-44.9%) for the 
haplo group and 23.9% (95% CI,  4.6-51.6%) for the 
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Table 2　 Patient characteristics
Characteristic Haplo (n＝20) Control (n＝13) P
Years of age at second SCT,  median (range) 49.5 (19-64) 54 (19-69) 0.58
Male,  n (%) 14 (70.0) 5 (38.5) 0.148
HCT-CI total scores,  median (range) 1 (0-6) 1 (0-3) 0.431
Disease status at ﬁrst SCT,  n (%)
　CR 14 (70.0) 9 (69.2) 1
　No CR  6 (30.0) 4 (30.8)
HPC for ﬁrst SCT,  n (%)
　rBMT 1 (5.0) 1(7.7) 0.31
　rPBSCT 9 (45.0) 5 (38.5)
　UR-BMT 6 (30.0) 2 (15.4)
　CBT 2 (10.0) 5 (38.5)
　Haploidentical 2 (10.0) 0 (0.0)
Preparative regimen: ﬁrst SCT,  n (%)
　BU-based 7 (35.0) 3 (23.1) 0.097
　TBI-based 12 (60.0) 5 (38.5)
　Others 1 (5.0) 4 (30.8)
　Unknown 0 (0.0) 1 (7.7)
Interval no. of days to relapse after ﬁrst SCT,  median (range) 232.5 (57-1,004) 667 (84-2,235) 0.009＊
Time between relapse and 2nd SCT,  median (range) 142.5 (24-723) 165 (85-888) 0.428
No. of days between ﬁrst and second SCT,  median (range) 388 (85-1,144) 833 (252-3,123) 0.027＊
Period of 2nd transplant
　2007 to 2011 5 (25.0) 6 (46.2) 0.27
　2012 to 2016 15 (75.0) 7 (53.8)
Diagnosis for second SCT,  n (%)
　AML 11 (55.0) 6 (46.2) 0.839
　MDS 2 (10.0) 1 (7.7)
　ALL 3 (15.0) 3 (23.1)
　ML 4 (20.0) 2 (15.4)
　ATL 0 (0.0) 1 (7.7)
Same diagnosis for ﬁrst and second SCT,  n (%) 20 (100.0) 11 (84.6) 0.148
Disease status at second SCT,  n (%)
　CR 9 (45.0) 7 (53.8) 0.728
　No CR 11 (55.0) 6 (46.2)
DLI before second SCT,  n (%) 6 (30.0) 1 (7.7) 0.202
Conditioning intensity for second SCT,  n (%)
　MAC 5 (25.0) 3 (23.1) 1.000
　RIC 15 (75.0) 10 (76.9)
SCT,  stem cell transplantation; MAC,  myeloablative conditioning; RIC,  reduced intensity; HCT-CI,  hematopoietic cell transplanta-
tion-speciﬁc comorbidity index; PBSCT,  peripheral blood SCT; BMT,  bone marrow transplantation; r,  related; UR,  unrelated; CBT,  cord 
blood transplantation; AML,  acute myeloid leukemia; MDS,  myelodysplastic syndrome; ALL,  acute lymphoblastic leukemia; ML,  malig-
nant lymphoma; ATL,  adult T-cell leukemia. ＊P＜0.05
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Table 3　 Outcomes of second transplant
Characteristic Haplo (n＝20) Control (n＝13) P
Donor engraftment,  n (%) 18 (90.0) 10 (76.9) 0.36
No. of days until PMN ＞500/µL,  median (range);
n=18,  haplo; n=10,  control
10.5 (9-23) 16 (12-21) 0.001
No. of days until platelet count ＞20,000/µL,  median (range);
n＝12,  haplo; n＝10,  control
16 (10-82) 20.5 (14-70) 0.06
Chronic GVHD
　None 9 (75.0) 6 (60.0) 0.348
　Limited 0 (0.0) 2 (20.0)
　Extensive 3 (25.0) 2 (20.0)
Follow-up survivors,  median days (range) 1,276 (584-1,403) 2,307.5 (505-3,747) 0.624
OS at 3 years (%),  (95% CI) 25.0 (9.1-44.9) 44.9 (17.7-69.0) 0.366
PFS at 3 yeasr (%),  (95% CI) 25.0 (9.1-44.9) 23.9 (4.6-51.6) 0.461
CI relapse at 3 years (%),  (95% CI) 25.0 (8.5-45.9) 28.6 (4.8-59.7) 0.794
CI of NRM at 3 years (%),  (95% CI) 50.0 (26.0-70.0) 47.4 (17.7-72.5) 0.755
CI of aGVHD II-IV at 120 days (%),  (95% CI) 30.0 (11.4-51.3) 46.2 (17.0-71.4) 0.304
CI of aGVHD III-IV at 120 days (%),  (95% CI) 20.0 (5.7-40.5) 15.4 (2.1-40.2) 0.742
NRM,  non-relapse mortality; aGVHD,  acute graft-vs.-host disease; CI,  cumulative incidences; OS,  overall survival; PFS,  progres-
sion-free survival.
Fig. 1　 A,  OS after second 
SCT; B,  PFS after second SCT.
Fig. 2　 A,  OS after second SCT 
(haplo vs. control); B,  PFS after 
second SCT (haplo vs. control).
control group (p = 0.461) (Fig. 2B,  Table 3).
The results of univariate and multivariate time-to-
event Cox regression analyses of OS and PFS are shown 
in Table 4A and B.  The effects of donor type (haplo vs. 
conventional),  conditioning regimen (MAC vs. RIC),  
and older patient age were not significant as univariate 
risk factors for OS or PFS.  The multivariate analyses 
showed that non-complete response (CR) status at the 
second SCT (hazard ratio (HR) 2.41,  95% CI 1.01-5.74;  
p = 0.047),  a < 1-year interval to relapse after the first 
SCT (HR 3.23,  95% CI 1.15-9.06; p = 0.026),  and an 
HCT-CI score ≥ 3 (HR 5.85,  95% CI 1.99-17.17;  
p = 0.0013) were significantly associated with poor PFS.
Relapse and NRM. The CIR at 3 years were 
25.0% (95% CI 8.5-45.9%) and 28.6% (95% CI 4.8-
59.7%) for the haplo and control groups,  respectively 
(p = 0.794; Fig. 3A,  Table 3).  The cumulative incidence 
of NRM at 3 years were 50.0% (95% CI,  26.0-70.0%) for 
the haplo group and 47.4% (95% CI,  17.7-72.5%) for 
the control group (p = 0.755; Fig. 3B,  Table 3).  Neither 
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Table 4A　 Univariate and multivariable risk factors for OS
Factors UnivariateHR (95% CI) P
Multivariate
HR (95% CI) P
Non-CR status at second SCT 2.83 (1.19-6.72) 0.019 2.39 (0.98-5.80) 0.055
Interval to relapse after ﬁrst SCT ＜1 year 2.16 (0.89-5.23) 0.088 2.59 (0.98-6.87) 0.055
HCT-CI total score ＞3 3.12 (1.25-7.82) 0.015 4.64 (1.69-12.72) 0.0029
Transplant (haplo vs. conventional) 1.46 (0.64-3.38) 0.37
Conditioning regimen (MAC vs. RIC) 1.46 (0.54-3.92) 0.46
Patient age ＞51 years 1.08 (0.48-2.4) 0.86
Table 4B　 Univariate and multivariable risk factors for PFS
Factors UnivariateHR (95% CI) P
Multivariate
HR (95% CI) P
Non-CR status at second SCT 2.86 (1.2-6.82) 0.018 2.41 (1.01-5.74) 0.047
Interval to relapse after ﬁrst SCT ＜1 year 2.12 (0.87-5.13) 0.097 3.23 (1.15-9.06) 0.026
HCT-CI total score ＞3 3.49 (1.41-8.63) 0.0068 5.85 (1.99-17.17) 0.0013
Transplant (haplo vs. conventional) 1.37 (0.59-3.16) 0.46
Conditioning regimen (MAC vs. RIC) 1.28 (0.55-3.01) 0.57
Patient age ＞51 years 1.10 (0.49-2.45) 0.83
SCT,  stem cell transplantation; HCT-CI,  hematopoietic cell transplantation-speciﬁc comorbidity index; MAC,  myeloablative condition-
ing; RIC,  reduced intensity.
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Fig. 3　 A,  Cumulative incidence of relapse after second SCT (haplo vs. control); B,  Cumulative incidence of non-relapse mortality after 
second SCT (haplo vs. control).
CIR nor NRM showed a significant differences between 
the groups.
In the control group,  there were 2 patients who 
relapsed more than 2 years after the second SCT.  Both 
patients were diagnosed as Ph + ALL and they were 
treated with a tyrosine kinase inhibitor after the first 
SCT,  which may have influenced their late-onset 
relapse.  Subsequently,  both patients underwent a third 
SCT (CBT and haplo-PBSCT) and died with pneumo-
nia or thrombotic micro-angiopathies.
GVHD. The CIs of grades II-IV acute GVHD at 
120 days were 30.0% (95% CI,  11.4-51.3%) and 46.2% 
(95% CI,  17.0-71.4%) for the haplo and control groups,  
respectively (p = 0.304) (Fig. 4A,  Table 3).  The CIs of 
grades III-IV acute GVHD at 120 days were 20.0% 
(95% CI,  5.7-40.5%) and 15.4% (95% CI,  2.1-40.2%) 
for the haplo and control groups,  respectively 
(p = 0.742) (Fig. 4B,  Table 3).  There were no significant 
differences between the haplo and control groups.  For 
chronic GVHD,  19 patients (11 in the haplo group,  8 in 
the control group) who survived for more than 100 days 
were evaluated; 3 patients (25.0%) in the haplo group 
and 2 (20.0%) in the control group developed extensive 
chronic GVHD (p = 0.348) (Table 3).
Engraftment. The outcomes of engraftment after 
the second SCTs are also shown in Table 3.  The hema-
topoietic engraftments were confirmed in 18 patients 
(90.0%) in the haplo group and 10 (76.9%) in the con-
trol group (p = 0.36).  The median time to neutrophil 
recovery (absolute neutrophil count > 0.5 × 109/μL) for 
the haplo group was 10.5 days (range 9-23 days),  which 
was significantly shorter than that for the control group 
(median 16 days,  range 12-21 days) (p = 0.001).  Among 
the 18 patients who achieved neutrophil engraftment 
after a haplo-SCT,  6 had no platelet recovery due to 
relapse or NRM.  The remaining 20 patients (12 in the 
haplo group and 8 in the control group) achieved an 
unsupported platelet count of 20 × 109/μL at a median 
time of 16 days (range 10-82 days) in the haplo group 
and 20.5 days (range 14-70 days) in the control group 
(p = 0.06).  A cumulative incidence survey for neutro-
phil and platelet engraftment showed no significant 
difference between the haplo and control groups (neu-
trophil engraftment: p = 0.0609,  platelet engraftment:  
p = 0.414) (Fig. 5A,  B).
Cause of death. The causes of death after the sec-
ond SCTs are shown in Table 5.  As mentioned above,  
two patients underwent a third SCT for relapse after 
their second SCT,  and they were excluded from this 
analysis.  In both the haplo and control groups,  the 
main cause of NRM was infection,  including sepsis,  
bacterial pneumonia,  CMV pneumonia,  invasive 
aspergillosis,  brain abscess,  and HHV-6 encephalitis.  
Other causes of death included disease relapse,  acute 
GVHD,  veno-occlusive disease,  and acute renal failure.  
There were no significant differences in the causes of 
death between the haplo and control groups (p = 0.785).
Discussion
Allogeneic transplantation represents the only 
potentially curative therapy for most patients who have 
relapsed after a first SCT,  but it is performed infre-
quently because of its substantial morbidity and mortal-
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Fig. 4　 A,  Cumulative incidence of grade II to IV acute GVHD after second SCT (haplo vs. control); B,  Cumulative incidence of grade 
III to IV acute GVHD after second SCT (haplo vs. control).
ity [2].  To avoid excessive toxicity,  non-myeloablative 
conditioning has been used as a second SCT [2 , 15].  
Another difficulty in conducting a second SCT is donor 
availability.  Because of the disease aggressiveness and 
the patient’s poor physical condition,  a rapidly accessi-
ble donor graft is needed.  Due to readily available 
donors,  haploidentical transplants have become more 
popular in recent years,  supported by the substantial 
improvements in transplant procedures such as using a 
relatively high dose of anti-T lymphocyte globulin 
(ATG) [3 , 16-18],  post-transplantation cyclophospha-
mide[5-8 , 19 , 20],  and ex- vivo T-cell depletion [21 , 22].
The combination of low-dose ATG and GVHD pro-
phylaxis consisting of tacrolimus and methylpredniso-
lone is another strategy for conducting haplo-SCT safely 
in patients at an advanced stage or those at high risk for 
relapse[3 , 16 , 23].  For these reasons,  haplo-SCT for 
relapsed patients after a first allo-SCT is increasing in 
clinical practice.
In an earlier study,  seven patients who experienced 
relapse within 1 year of their first SCT and underwent a 
haplo-SCT as a second SCT showed a 2-year OS rate of 
42.9% [24].  However,  no other studies of larger cohorts 
have evaluated haplo-SCTs for relapsed patients as a 
second SCT.  In the present study,  we performed a ret-
rospective single-center review of patients who under-
went a second SCT for relapse after a first allo-SCT,  and 
we evaluated the efficacy of haplo-SCT in this setting.
According to prior studies,  patients who undergo a 
second allo-SCT for relapsed AML have OS rates in the 
range of 11-42% [1 , 2 , 15 , 25-27].  Christopeit et al.  per-
formed a retrospective study of 179 patients who 
underwent a second SCT for relapse after a first allo-
SCT,  and they reported that the 2-year OS was 25% 
[26].  Eapen et al.  analyzed the outcome of 279 patients 
who relapsed after HLA-identical sibling transplanta-
tion and underwent a second allo-SCT,  and they 
reported a 5-year OS of 28% [27].  Bosi et al.  performed 
a retrospective study of 170 patients who underwent a 
second SCT for acute leukemia and experienced relapse 
after their first SCT,  and they reported 5-year OS and 
PFS rates of 26% and 25%,  respectively [25].  The OS 
and PFS of our patients seem comparable to these ear-
lier reports.
It has been suggested that good-risk prognostic fac-
tors for the outcome of second SCTs include younger 
patient age,  longer duration between the first SCT and 
relapse,  CR status at the time of the second SCT,  RIC 
for the second SCT,  and the use of an HLA-identical 
related donor for the first SCT [1 , 2 , 15 , 25-27].  We 
therefore evaluated these factors among our patients in 
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Table 5　 Cause of death
Cause of death Haplo(n＝15)
Control
(n＝7) P
Relapse,  n (%) 5 (33.3) 1 (14.3) 0.785
NRM
Infection,  n (%) 7 (46.7) 5 (71.4)
Acute GVHD,  n (%) 1 (6.7) 0 (0.0)
VOD,  n (%) 1 (6.7) 1 (14.3)
Acute renal failure,  n (%) 1 (6.7) 0 (0.0)
Excluded two patients who underwent a third SCT.
NRM,  non-relapse mortality; aGVHD,  acute graft-vs.-host disease;  
VOD,  veno-occlusive disease.
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Fig. 5　 A,  Neutrophil engraftment after second SCT (haplo vs. control); B,  Platelet engraftment after second SCT (haplo vs. control).
univariate and multivariate analyses,  and the results 
confirmed that non-CR status at the second SCT,  
relapse earlier than 1 year after the first SCT,  and a poor 
HCT-CI score were significantly associated with shorter 
PFS.  These factors might reflect the aggressiveness of 
our patients’ disease.
Our comparison of the haplo-SCTs and conven-
tional SCTs showed equivalent outcomes in the OS and 
PFS of the recipients.  The results of our analysis also 
demonstrated equivalent cumulative incidences of 
relapse and NRM between the haplo and control 
groups.  The comparison of the patients’ characteristics 
showed that the time from the first SCT to relapse in the 
haplo group was significantly shorter than that in the 
control group (median 232.5 days vs. 667 days,  
p = 0.009).  As we mentioned,  a shorter-period relapse 
after the first SCT contributed to the poor outcomes 
after the second SCTs.  Although the disease status at 
the first and the second SCTs were not significantly dif-
ferent between the haplo and control groups,  this earlier 
relapse suggests that the haplo-SCT group might have 
included patients with more aggressive relapsed disease 
compared to the control group.  Thus,  the equivalence 
in basic clinical outcomes after haplo-SCT and conven-
tional SCT may suggest a relatively higher potential for 
GVH effects in haplo-SCT.
On the other hand,  the median time from the 
relapse to the second SCT was not significantly different 
between the haplo and control groups.  We could not 
directly confirm a more rapid preparation of haplo-do-
nors compared to other conventional donors,  but as we 
observed at the period of the second SCT,  the number 
of patients who undergoing a haplo-SCT is increasing.  
The accessibility of haplo-donors may contribute to this 
expansion of second SCTs for relapsed patients.
In this study,  the cumulative incidences of acute 
GVHD and chronic GVHD were comparable between 
the haplo-SCT recipients and conventional-SCT recipi-
ents.  Studies of second conventional-SCTs for relapsed 
leukemia patients after their first SCTs have reported 
cumulative incidences of grade II-IV acute GVHD of 
22.5-53% [25-27].  These data are similar to those of our 
cohorts.  The primary concern about haploidentical 
transplantation is the intense bidirectional alloreactiv-
ity,  which potentially results in high incidences of graft 
failure and severe GVHD.  However,  haplo-SCT was 
reported to be associated with a low incidence of acute 
GVHD (in the range of 14-41%),  which is comparable 
to the incidence observed in conventional SCTs 
[5-8 , 16 , 17 , 20].  In our cohort,  even in the second SCT 
setting,  there was no increase in the incidence of severe 
acute GVHD after haplo-SCT.  In vivo T-cell depletion 
by ATG and the early use of methylprednisolone as 
GVHD prophylaxis might have contributed to the 
decrease of severe acute GVHD.
Haplo-SCT using T cell-depleted grafts and 
post-transplant cyclophosphamide (PTCy) are associ-
ated with a lower incidence of chronic GVHD com-
pared to transplants from conventional donors.  
[5 , 7 , 20] In general,  the use of peripheral blood stem 
cells (PBSCs) is a risk factor for chronic GVHD;  
however,  several studies that have used PBSCs alone as 
a transplant graft have indicated that the incidence of 
moderate to severe chronic GVHD in haplo-SCT recip-
ients is still 25-28% [6 , 7].  A study of haplo-SCTs with 
low-dose ATG revealed a 20% incidence of chronic 
extensive GVHD [16]; our results are similar.  These 
findings suggest that haplo-SCT is sufficient to avoid 
symptomatic chronic GVHD.
We observed that the cumulative incidence of neu-
trophil and platelet engraftment after SCT was equiva-
lent in the haplo and control groups.  In addition,  hap-
lo-SCT was associated with rapid hematopoietic 
recovery; the median times for neutrophil recovery 
was 10.5 days,  which is similar to other studies of hap-
lo-SCT with low-dose ATG [3 , 16].  By contrast,  
patients who underwent a haplo-SCT with PTCy have 
been reported to show slower neutrophil recovery than 
those who underwent HLA-matched unrelated trans-
plantation [5-8].  Even in cases in shich a PB graft is 
used,  the neutrophil and platelet recovery after hap-
lo-SCT with PTCy were delayed (median time to neu-
trophil engraftment,  16 days,  median time to platelet 
engraftment,  22-26 days) [7 , 8].  The rapid achieve-
ment of engraftment after transplantation is very 
important to avoid serious bacterial or fungal infec-
tions.  Although there have been no direct comparisons,  
a haplo-SCT with low-dose ATG might be preferable to 
haplo-SCT with PTCy,  especially for patients with 
active infection at the second SCT.
Our study has several limitations.  As a retrospective 
acquisition of data,  the possibility of selection bias can-
not be completely excluded.  In addition,  statistically 
significant differences were not detected due to the 
small sample size and potential lack of power.  
Moreover,  our median follow-up time for survivors was 
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too short to draw conclusions.  Despite these limita-
tions,  our study is the first analysis to compare trans-
plantation outcomes between haploidentical versus 
conventional SCTs for relapsed patients after a first allo-
SCT at a single-institute during the same period of time.  
Our results suggest that patients with indications for 
transplantation may undergo a transplantation using a 
haploidentical donor as safely as transplantation using a 
conventional matched donor.
Our analysis revealed that the outcomes of patients 
with relapse after s first SCT treated with transplants 
from HLA-haploidentical donors are comparable to the 
outcomes of patients treated with conventional trans-
plants.  These results need further confirmation in a 
longer follow-up and a larger-scale study.  As it is usu-
ally easier to obtain a second graft from a family mem-
ber than to activate an unrelated donor graft,  SCT from 
a haploidentical donor could provide a promising alter-
native strategy in clinically difficult and time-con-
strained situations.  Further improvements in the 
reduction of relapse and other complications of hap-
lo-SCT with low-dose ATG in the near future will 
broaden the treatment options for better clinical out-
comes.
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